Abeona Therapeutics Inc.

NasdaqCM:ABEO Stok Raporu

Piyasa değeri: US$276.3m

Abeona Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Abeona Therapeutics kazanç ve gelirinin sırasıyla yıllık 53.4% ve 62.7% oranında artması tahmin edilirken, EPS'nin yıllık 56.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

53.4%

Kazanç büyüme oranı

56.3%

EPS büyüme oranı

Biotechs kazanç büyümesi28.0%
Gelir büyüme oranı62.7%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Good

Son güncelleme31 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Sep 23
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

May 01
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Jan 04
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16
Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31
Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28
Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21
Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19
How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15
What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:ABEO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202671-40-31-596
12/31/202514-71-52-666
12/31/20240-62-60-646
6/30/2024N/A-53-44-42N/A
3/31/20244-77-41-40N/A
12/31/20234-54-37-37N/A
9/30/20234-45-42-42N/A
6/30/20234-39-43-43N/A
3/31/20231-31-42-42N/A
12/31/20221-43-44-43N/A
9/30/20224-83-63-60N/A
6/30/20224-84-67-63N/A
3/31/20223-91-70-66N/A
12/31/20213-85-70-66N/A
9/30/20213-54-38-37N/A
6/30/202110-54-38-37N/A
3/31/202110-52-37-35N/A
12/31/202010-84-36-35N/A
9/30/20207-85-49-48N/A
6/30/2020N/A-95-57-55N/A
3/31/2020N/A-106-67-61N/A
12/31/2019N/A-76-69-63N/A
9/30/20190-77-83-66N/A
6/30/20192-76-74-56N/A
3/31/20192-65-67-50N/A
12/31/20183-57-59-39N/A
9/30/20183-48-36-27N/A
6/30/20181-37-33-25N/A
3/31/20181-33N/A-21N/A
12/31/20171-27N/A-23N/A
9/30/20171-26N/A-21N/A
6/30/20171-23N/A-18N/A
3/31/20171-22N/A-16N/A
12/31/20161-22N/A-13N/A
9/30/20161-17N/A-12N/A
6/30/20161-21N/A-11N/A
3/31/20161-18N/A-10N/A
12/31/20151-15N/A-10N/A
9/30/20151-25N/A-9N/A
6/30/20151-21N/A-6N/A
3/31/20151-30N/A-5N/A
12/31/20141-30N/A-2N/A
9/30/20141-19N/A-1N/A
6/30/20141-17N/A-2N/A
3/31/20141-3N/A0N/A
12/31/201322N/A0N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ABEO önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ABEO önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ABEO önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ABEO şirketinin gelirinin (yıllık 62.7% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ABEO şirketinin gelirinin (yıllık 62.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ABEO 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin